4-amino-N-butyl-N-phenylbenzenesulfonamide | 107413-33-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-N-butyl-N-phenylbenzenesulfonamide
• 英文别名: 4-Amino-N-butyl-N-phenylbenzene-1-sulfonamide
• CAS: 107413-33-2
• 化学式: C₁₆H₂₀N₂O₂S
• 分子量: 304.413
• InChiKey: MOHJJPOPTUEURQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-butyl-4-nitro-N-phenylbenzenesulfonamide 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 7.0h， 生成 4-amino-N-butyl-N-phenylbenzenesulfonamide
  参考文献：
  名称：

  [EN] N-TYPE CALCIUM CHANNEL INHIBITOR
  [FR] INHIBITEUR DE CANAL DE CALCIUM DE TYPE N

  摘要：

  This invention relates to an N-type calcium channel inhibitor drug containing a compound having an N-type calcium channel inhibitory action represented by the general formula (I) (wherein the symbols are as described in the specification), its salt, solvate, or prodrug. Since the compound of the present invention has an N-type calcium channel inhibitory action, it is useful as a preventive and/or therapeutic agent for N-type calcium channel-mediated diseases such as pain (e.g., acute pain, chronic pain, postoperative pain, cancer pain, neuropathic pain, infectious pain, etc.), cerebral infarction, transient cerebral ischemic attack, brain and spinal cord disorders after cardiac surgery, spinal cord vascular disorders, stress-induced hypertension, neurosis, epilepsy, asthma, frequent urination, eye diseases, etc.

  公开号：

  WO2006038594A1

文献信息

• [EN] N-TYPE CALCIUM CHANNEL INHIBITOR<br/>[FR] INHIBITEUR DE CANAL DE CALCIUM DE TYPE N
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2006038594A1

  公开（公告）日：2006-04-13

  　本発明は、一般式（Ｉ） （式中の記号は明細書中に記載の通り）で示されるＮ型カルシウムチャネル阻害作用を有する化合物、その塩もしくはそれらの溶媒和物またはそのプロドラッグを含有してなるＮ型カルシウムチャネル阻害薬に関する。　本発明化合物は、Ｎ型カルシウムチャネル阻害作用を有するので、Ｎ型カルシウムチャネル介在性疾患、例えば疼痛（例えば、急性痛、慢性痛、術後痛、癌性疼痛、神経痛、感染性疼痛等）、脳梗塞、一過性脳虚血発作、心臓手術後の脳脊髄障害、脊髄血管障害、ストレス性高血圧、神経症、てんかん、喘息、頻尿、眼疾患等の予防および／または治療剤として有用である。

  This invention relates to an N-type calcium channel inhibitor drug containing a compound having an N-type calcium channel inhibitory action represented by the general formula (I) (wherein the symbols are as described in the specification), its salt, solvate, or prodrug. Since the compound of the present invention has an N-type calcium channel inhibitory action, it is useful as a preventive and/or therapeutic agent for N-type calcium channel-mediated diseases such as pain (e.g., acute pain, chronic pain, postoperative pain, cancer pain, neuropathic pain, infectious pain, etc.), cerebral infarction, transient cerebral ischemic attack, brain and spinal cord disorders after cardiac surgery, spinal cord vascular disorders, stress-induced hypertension, neurosis, epilepsy, asthma, frequent urination, eye diseases, etc.